Thoralf Lange, Thomas Ernst, Franz X. Gruber, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus and Markus Pfirrmann (2013) “The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia”, Haematologica. Pavia, Italy, 98(5), pp. 714-717. doi: 10.3324/haematol.2012.068890.